Nanogroup SA
WSE:NNG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nanogroup SA
Free Cash Flow
Nanogroup SA
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nanogroup SA
WSE:NNG
|
Free Cash Flow
-zł16m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Free Cash Flow
-zł1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Free Cash Flow
-zł121.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-19%
|
|
|
S
|
Selvita SA
WSE:SLV
|
Free Cash Flow
zł62.1m
|
CAGR 3-Years
24%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
Nanogroup SA
Glance View
NanoGroup SA engages in the medical research and development. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2017-12-21. The firm focuses on the investment in, as well as development of advanced biotechnological projects in the areas of cancer prevention, early diagnosis, targeted cancer therapies and ontological rehabilitation. Its projects portfolio includes NanoVelos, which is responsible for the creation of drug delivery system for proven oncologic medicines to optimize their performance; NanoSanguis, which develops artificial blood to keep alive patients wounded in accidents, as well as a system, named Organ farm, to preserve human organs ex vivo, and NanoThea, which is dedicated to technology that detects cancer cells in early stage.
See Also
What is Nanogroup SA's Free Cash Flow?
Free Cash Flow
-16m
PLN
Based on the financial report for Sep 30, 2025, Nanogroup SA's Free Cash Flow amounts to -16m PLN.
What is Nanogroup SA's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-34%
Over the last year, the Free Cash Flow growth was -1 608%. The average annual Free Cash Flow growth rates for Nanogroup SA have been -74% over the past three years , -34% over the past five years .
